Wed, April 27, 2022
Philip Bowes v UK Anti-Doping (First instance & Appeal)
To optimise for archiving, the original image and related documents associated with this article have been removed.
A decision in the appeal of Philip Bowes v UK Anti-Doping (UKAD) has been published by the National Anti-Doping Panel (NADP), along with the first instance decision.
On 2 September 2020, Mr Philip Bowes, a Professional Boxer, provided a urine Sample In-Competition. The Sample returned an Adverse Analytical Finding (AAF) for Ostarine.
Mr Bowes was subsequently charged on 16 October 2020, with a breach of ADR Article 2.1 for the Presence of a Prohibited Substance or its Metabolites or Markers in his Sample. Mr Bowes admitted the Anti-Doping Rule Violation (ADRV) but contented that he had not committed that ADRV intentionally. The NADP Tribunal, consisting of Kate Gallafent QC, Lorraine Johnson and Dr Terry Crystal found Mr Bowes had committed an ADRV pursuant to ADR Article 2.1 and that he had not discharged the burden on him under ADR Article 10.2.1(a) to establish the ADRV was not intentional. A period of Ineligibility of four years was imposed.
On 30 August 2021, Mr Bowes appealed the decision issued on 5 August 2021. The NADP Appeal Tribunal, consisting of William Norris QC, Dr Tim Rogers and Professor Kitrina Douglas found that the Tribunal at first instance were correct to reach their conclusion and therefore the appeal was dismissed.
Copies of the full decisions can be accessed via the related documents tab on the right-hand side.
The National Anti-Doping Panel (NADP) is the United Kingdom’s independent tribunal responsible for adjudicating anti-doping disputes in sport. It is operated by Sport Resolutions and is entirely independent of UK Anti-Doping who is responsible for investigating, charging and prosecuting cases before the NADP.
